LAMC2 and neoplasm: To test the therapeutic potential of targeting the Tum_1 subpopulation or its associated pathways, preclinical validation using patient‐derived organoids and xenograft models is needed to assess the role of Tum_1‐related pathways, such as LAMC2, in tumor progression, as well as the efficacy and safety of targeted therapies.